New­ly part­nered with blue­bird, Grit­stone seeks $80M IPO in fi­nal dash for clin­ic

Since launch­ing in 2015, Grit­stone On­col­o­gy has court­ed some well-heeled in­vestors and high pro­file part­ners to bet on its neo-anti­gen R&D ef­fort. Now, it is ready to find a new group of sup­port­ers with an IPO.

The Emeryville, CA-based biotech is seek­ing $80 mil­lion to fol­low up two mega-rounds and a rel­a­tive­ly mod­est Se­ries C, fil­ing its S-1 on the same day it an­nounced a new TCR al­liance with blue­bird bio — a deal that, the pa­per­work re­vealed, could bring in $1.2 bil­lion in mile­stones in ad­di­tion to the $30 mil­lion to­tal in near-term cash.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER